What genetic and imaging tests are recommended to evaluate a patient for fragile X‑associated tremor/ataxia syndrome (FXTAS)?

Testing for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

Evaluate every patient suspected of FXTAS with FMR1 genetic testing to detect premutation alleles (55-200 CGG repeats) and brain MRI to identify characteristic white matter changes, particularly the middle cerebellar peduncle (MCP) sign.

Genetic Testing

Primary Diagnostic Test

• FMR1 gene CGG repeat analysis is the definitive genetic test for FXTAS 1
• Testing should quantify the number of CGG trinucleotide repeats in the 5' untranslated region of the FMR1 gene located at Xq27.3 1

CGG Repeat Classification and FXTAS Risk

CGG Repeat Range	Classification	FXTAS Risk
5-44	Normal	No risk [1]
45-54	Intermediate/gray zone	Rare cases reported, larger studies needed [1]
55-200	Premutation	FXTAS occurs in this range [1,2,3]
>200	Full mutation	Causes fragile X syndrome, not FXTAS [1]

Penetrance by Age and Sex

• Males with premutation: 40-45% develop FXTAS by age 50, increasing to over 60% by age 70 4, 3, 5
• Females with premutation: 8-16% develop FXTAS due to protective effect of second X chromosome 4, 3
• Penetrance increases with both advancing age and higher CGG repeat length 1
• Men with ≤70 CGG repeats have <1% risk of FXTAS, much lower than previously thought 6

Testing Methodology

Use combined PCR and Southern blot analysis or newer repeat-primed PCR methods 1

• Traditional PCR alone may miss full mutations in mosaic samples spanning premutation and full mutation ranges 1
• Southern blot analysis should accompany traditional PCR to detect methylation status and full mutations 1
• Newer triplet repeat-primed PCR or methylation PCR can eliminate the need for Southern blot on every sample 1
• Controls representing difficult-to-recognize genotypes (premutations and diffuse full mutations) are essential for quality assurance 1

Neuroimaging Studies

Brain MRI: Essential for Diagnosis

MRI is mandatory to document white matter disease, a primary component of FXTAS diagnostic criteria 5

Major Radiological Features

Two major radiological criteria now define FXTAS imaging 4:

1. Middle cerebellar peduncle (MCP) sign: Symmetric T2 hyperintensity in the middle cerebellar peduncles, present in the majority of FXTAS patients 2, 4
2. Corpus callosum splenium hyperintensity: T2 hyperintensity in the splenium of the corpus callosum, recently added as a major diagnostic criterion 4

Additional Imaging Findings

• T2 hyperintensities in the pons, insula, and periventricular white matter 4
• Deep and subependymal cerebral white matter signal alterations 2
• Generalized cortical and subcortical atrophy 2
• Cerebellar atrophy 2, 4
• Symmetric high-intensity band-like signal at the cerebral corticomedullary junction on diffusion-weighted imaging (DWI) 7
• Microbleeds and iron deposition 5

Advanced Imaging Considerations

• Ultra-high-field 7-Tesla MRI can provide enhanced visualization of FXTAS features 7
• DWI findings may overlap with adult-onset neuronal intranuclear inclusion disease (NIID), creating diagnostic confusion 7

Clinical Algorithm for FXTAS Testing

When to Order FMR1 Testing

Consider FXTAS diagnosis and order FMR1 premutation testing if a patient over age 50 meets ANY of the following 8:

1. Presents with cerebellar ataxia and/or intention tremor with mild parkinsonism 8
2. Has MCP sign, global cerebellar and cerebral atrophy, and/or subcortical white matter lesions on MRI 8
3. Has family history of fragile X-related disorders (intellectual disability, autism, premature ovarian failure) plus neurological signs consistent with FXTAS 8

Supportive Clinical Features

• Peripheral neuropathy 8
• Executive function deficits 8
• Anxiety or depression 8
• Dementia (develops in 50% of males) 3
• Pain (present in approximately 50% of patients) 5
• Dysautonomia 2

Core Motor Features

• Action tremor or intention tremor (primary presenting symptom) 2, 3
• Cerebellar gait ataxia 2
• Parkinsonism (frequent associated finding) 2
• Note: 20% of patients present with ataxia alone without tremor 3

Critical Diagnostic Pitfalls

Avoid Misdiagnosis

• FXTAS imaging findings overlap significantly with NIID, including DWI corticomedullary junction hyperintensity and cerebellar signal changes 7
• Both FXTAS and NIID manifest intranuclear inclusion bodies on pathology, creating potential for misdiagnosis 7
• Genetic analysis is essential in all cases with suspected NIID or FXTAS for confirmation 7

Co-occurring Pathology

• Parkinson disease and Alzheimer disease can co-occur with FXTAS 5
• Lewy bodies are found in 10% of FXTAS brains at autopsy 5

Population Screening Context

• The premutation occurs in approximately 1:200-250 females and 1:400-800 males 3, 5
• FXTAS is likely one of the most common single-gene disorders leading to neurodegeneration in males 2
• Currently under-diagnosed due to recent discovery and lack of awareness 2, 4

Genetic Counseling After Diagnosis

Family Implications

• All first-degree relatives of a premutation carrier should be offered FMR1 testing regardless of gender 9
• Female premutation carriers have 20% lifetime risk of fragile X-associated primary ovarian insufficiency (FXPOI), especially with >80 CGG repeats 1, 9
• Premutation alleles are unstable during maternal transmission and can expand to full mutations causing fragile X syndrome in offspring 1, 9
• Women with premutations should be offered prenatal diagnostic testing for all pregnancies 1, 9

Pathogenic Mechanism

• FXTAS results from RNA toxicity due to elevated FMR1 mRNA levels (2-8 fold increase) in premutation carriers 2, 3, 5
• The toxic gain-of-function mechanism differs from fragile X syndrome, which results from loss of FMRP protein 3
• Elevated mRNA can sequester proteins important for neuronal function 5
• Intranuclear inclusions contain elevated SUMO1/2 proteins, suggesting altered proteasomal function 5